Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $13.07 billion. The enterprise value is $11.75 billion.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 123.70 million shares outstanding. The number of shares has increased by 33.12% in one year.
| Current Share Class | 123.70M |
| Shares Outstanding | 123.70M |
| Shares Change (YoY) | +33.12% |
| Shares Change (QoQ) | +4.98% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 93.69% |
| Float | 114.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.93 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.88, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.88 |
| Quick Ratio | 17.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.08% and return on invested capital (ROIC) is -20.85%.
| Return on Equity (ROE) | -29.08% |
| Return on Assets (ROA) | -20.10% |
| Return on Capital (ROIC) | -20.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.96M |
| Employee Count | 254 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +106.51% in the last 52 weeks. The beta is 1.01, so Vaxcyte's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +106.51% |
| 50-Day Moving Average | 109.96 |
| 200-Day Moving Average | 81.60 |
| Relative Strength Index (RSI) | 37.82 |
| Average Volume (20 Days) | 627,674 |
Short Selling Information
The latest short interest is 9.34 million, so 7.55% of the outstanding shares have been sold short.
| Short Interest | 9.34M |
| Short Previous Month | 9.65M |
| Short % of Shares Out | 7.55% |
| Short % of Float | 8.16% |
| Short Ratio (days to cover) | 12.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | -75.00M |
| Operating Income | -577.16M |
| Pretax Income | -497.19M |
| Net Income | -497.19M |
| EBITDA | -573.11M |
| EBIT | -577.16M |
| Earnings Per Share (EPS) | -$4.59 |
Full Income StatementBalance Sheet
The company has $1.45 billion in cash and $25.58 million in debt, giving a net cash position of $1.43 billion or $11.54 per share.
| Cash & Cash Equivalents | 1.45B |
| Total Debt | 25.58M |
| Net Cash | 1.43B |
| Net Cash Per Share | $11.54 |
| Equity (Book Value) | 1.99B |
| Book Value Per Share | 17.96 |
| Working Capital | 1.40B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$466.88 million and capital expenditures -$115.46 million, giving a free cash flow of -$582.34 million.
| Operating Cash Flow | -466.88M |
| Capital Expenditures | -115.46M |
| Free Cash Flow | -582.34M |
| FCF Per Share | -$4.71 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |